This book encompasses work on several inflammatory conditions where the immune system plays a role as a pathogenic mediator, but can be modulated by gene therapy. Examples of research in rheumatoid arthritis, multiple sclerosis, diabetes, transplantation and lupus erythematosus are reported, and a chapter on theoretical considerations for the use of gene therapy of salivary glands is also included. This is a timely book as there have been many advances in this field. However, some of the chapters include references up to 1997-1998 making them rather outdated.
The general therapy theme circles around the inhibition of immune reactions by shifting the cytokine balance using cytokine inhibitors or inhibitory cytokines that dampen Th1 (proinflammatory) reactions. In addition, researchers have used pro-apoptotic molecules such as FAS-L or inhibitors of accessory molecules (such as CTLA4 Ig). Not surprisingly, these have been found to be therapeutic in most of the experimental disease models studied.
In general, the use of adenovirus for therapy is discouraged throughout the different chapters because long-term expression is a requirement in these chronic conditions.
The quality of the chapters varies from very informative reviews that include information on clinical trials and outcome from studies using biologicals before the description of work on gene therapy, to theoretical chapters where descriptive non-peer-reviewed work is published for the first time.
For the expert, the collection of data about prophylactic use of gene therapy is disappointing. Only certain clinical situations such as transplantation may allow such an approach in a clinical setting. Certainly, we need to learn more about basic human immunology and pathology. Studies using human cells (also from patients) in SCID mice will allow us to obtain important information which is more relevant, long-term and accurate, as is described in one of the chapters.
Overall, the book is comprehensive and enlightens the reader about the usefulness of immunogenetic therapy in these conditions. The fact that so many similar mediators can influence disease in animal models of different pathologies, such as arthritis and organ transplantation, stresses the usefulness and pleiotropism of soluble mediators. It is also an important reminder that local therapy will be necessary in these conditions, as systemic therapy could be unsafe.
The emerging disciplines of tissue engineering (for example, hepatocytes secreting insulin) and immunosuppressive gene therapy are beginning to merge and their impact in inflammatory diseases will soon be felt in the clinical arena. 
